Literature DB >> 31148204

Thromboelastography-Guided Blood Component Use in Patients With Cirrhosis With Nonvariceal Bleeding: A Randomized Controlled Trial.

Manoj Kumar1, Juned Ahmad1, Rakhi Maiwall1, Ashok Choudhury1, Meenu Bajpai2, Lalita G Mitra3, Vandana Saluja3, Prashant Mohan Agarwal3, Chhagan Bihari4, Saggere Muralikrishna Shasthry1, Ankur Jindal1, Ankit Bhardwaj5, Guresh Kumar6, Shiv K Sarin1.   

Abstract

Thromboelastography (TEG) provides a more comprehensive global coagulation assessment than routine tests (international normalized ratio [INR] and platelet [PLT] count), and its use may avoid unnecessary blood component transfusion in patients with advanced cirrhosis and significant coagulopathy who have nonvariceal upper gastrointestinal (GI) bleeding. A total of 96 patients with significant coagulopathy (defined in this study as INR >1.8 and/or PLT count < 50 × 109 /L) and nonvariceal upper GI bleed (diagnosed after doing upper gastrointestinal endoscopy, which showed ongoing bleed from a nonvariceal source) were randomly allocated to TEG-guided transfusion strategy (TEG group; n = 49) or standard-of-care (SOC) group (n = 47). In the TEG group, only 26.5% patients were transfused with all three blood components (fresh frozen plasma [FFP], PLTs, and cryoprecipitate) versus 87.2% in the SOC group (P < 0.001). Although 7 (14.3%) patients in the TEG group received no blood component transfusion, there were no such patients in the SOC group (P = 0.012). Also, there was a significantly lower use of blood components (FFP, PLTs, and cryoprecipitate) in the TEG group compared with the SOC group. Failure to control bleed, failure to prevent rebleeds, and mortality between the two groups were similar.
Conclusion: In patients with advanced cirrhosis with coagulopathy and nonvariceal upper GI bleeding, TEG-guided transfusion strategy leads to a significantly lower use of blood components compared with SOC (transfusion guided by INR and PLT count), without an increase in failure to control bleed, failure to prevent rebleed, and mortality.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2019        PMID: 31148204     DOI: 10.1002/hep.30794

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  18 in total

1.  Features of Blood Clotting on Thromboelastography in Hospitalized Patients With Cirrhosis.

Authors:  Hani Shamseddeen; Kavish R Patidar; Marwan Ghabril; Archita P Desai; Lauren Nephew; Sandra Kuehl; Naga Chalasani; Eric S Orman
Journal:  Am J Med       Date:  2020-05-29       Impact factor: 4.965

Review 2.  Transfusion thresholds for guiding red blood cell transfusion.

Authors:  Jeffrey L Carson; Simon J Stanworth; Jane A Dennis; Marialena Trivella; Nareg Roubinian; Dean A Fergusson; Darrell Triulzi; Carolyn Dorée; Paul C Hébert
Journal:  Cochrane Database Syst Rev       Date:  2021-12-21

3.  Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.

Authors:  Maxime G Zermatten; Montserrat Fraga; Debora Bertaggia Calderara; Alessandro Aliotta; Darius Moradpour; Lorenzo Alberio
Journal:  JHEP Rep       Date:  2020-05-11

4.  Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis.

Authors:  Jassin Rashidi-Alavijeh; Ayse S Ceylan; Heiner Wedemeyer; Martin Kleefisch; Katharina Willuweit; Christian M Lange
Journal:  PLoS One       Date:  2020-07-28       Impact factor: 3.240

5.  Comparison of Thromboelastography and Conventional Coagulation Tests in Patients With Severe Liver Disease.

Authors:  Patryck Lloyd-Donald; Abhinav Vasudevan; Peter Angus; Paul Gow; Johan Mårtensson; Neil Glassford; Glenn M Eastwood; Graeme K Hart; Daryl Jones; Laurence Weinberg; Rinaldo Bellomo
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

6.  Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure-Related Bleeding in Decompensated Cirrhosis.

Authors:  Alberto Zanetto; Henry M Rinder; Marco Senzolo; Paolo Simioni; Guadalupe Garcia-Tsao
Journal:  Hepatol Commun       Date:  2020-12-12

7.  Tracheostomy in critically ill liver disease patients with coagulopathy: A retrospective study at a tertiary center.

Authors:  Vandana Saluja; Shilpa Tiwari; Lalita Gouri Mitra; Guresh Kumar; Rakhi Maiwall; V Rajan
Journal:  Int J Crit Illn Inj Sci       Date:  2020-12-29

Review 8.  The hemostatic and thrombotic complications of liver disease.

Authors:  Hannah Stowe McMurry; Janice Jou; Joseph Shatzel
Journal:  Eur J Haematol       Date:  2021-07-29       Impact factor: 2.997

9.  Rotational thrombelastometry (ROTEM) improves hemostasis assessment compared to conventional coagulation test in ACLF and Non-ACLF patients.

Authors:  Jessica Seeßle; Jan Löhr; Marietta Kirchner; Josefin Michaelis; Uta Merle
Journal:  BMC Gastroenterol       Date:  2020-08-17       Impact factor: 3.067

Review 10.  Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review.

Authors:  Stefano Ballestri; Mariano Capitelli; Maria Cristina Fontana; Dimitriy Arioli; Elisa Romagnoli; Catia Graziosi; Amedeo Lonardo; Marco Marietta; Francesco Dentali; Giorgio Cioni
Journal:  Adv Ther       Date:  2020-04-13       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.